2023
Folate Intake and Ovarian Cancer Risk among Women with Endometriosis: A Case–Control Study from the Ovarian Cancer Association Consortium
Gersekowski K, Ibiebele T, Group F, Doherty J, Harris H, Goodman M, Terry K, Wu A, Bandera E, Qin B, Ong J, Tyrer J, Dixon-Suen S, Modugno F, Risch H, Webb P. Folate Intake and Ovarian Cancer Risk among Women with Endometriosis: A Case–Control Study from the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers & Prevention 2023, 32: of1-of10. PMID: 37220873, PMCID: PMC10390886, DOI: 10.1158/1055-9965.epi-23-0121.Peer-Reviewed Original ResearchConceptsOvarian cancer riskHigh dietary folate intakeDietary folate intakeCase-control studyFolate intakeOvarian cancerOvarian Cancer Association ConsortiumCancer riskOdds ratioMendelian randomizationSelf-reported endometriosisSupplemental folate intakeHigh folate intakeHigh folate dietCancer-promoting effectsPooled analysisFolate dietPrecancerous lesionsFolate statusEndometriosisIncrease riskCancerCancer typesLogistic regressionIntake
2020
Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants
Barnes DR, Rookus MA, McGuffog L, Leslie G, Mooij TM, Dennis J, Mavaddat N, Adlard J, Ahmed M, Aittomäki K, Andrieu N, Andrulis IL, Arnold N, Arun BK, Azzollini J, Balmaña J, Barkardottir RB, Barrowdale D, Benitez J, Berthet P, Białkowska K, Blanco AM, Blok MJ, Bonanni B, Boonen SE, Borg Å, Bozsik A, Bradbury AR, Brennan P, Brewer C, Brunet J, Buys SS, Caldés T, Caligo MA, Campbell I, Christensen LL, Chung WK, Claes KBM, Colas C, Collonge-Rame M, Cook J, Daly M, Davidson R, de la Hoya M, de Putter R, Delnatte C, Devilee P, Diez O, Ding Y, Domchek S, Dorfling C, Dumont M, Eeles R, Ejlertsen B, Engel C, Evans D, Faivre L, Foretova L, Fostira F, Friedlander M, Friedman E, Frost D, Ganz P, Garber J, Gehrig A, Gerdes A, Gesta P, Giraud S, Glendon G, Godwin A, Goldgar D, González-Neira A, Greene M, Gschwantler-Kaulich D, Hahnen E, Hamann U, Hanson H, Hentschel J, Hogervorst F, Hooning M, Horvath J, Hu C, Hulick P, Imyanitov E, Isaacs C, Izatt L, Izquierdo A, Jakubowska A, James P, Janavicius R, John E, Joseph V, Karlan B, Kast K, Koudijs M, Kruse T, Kwong A, Laitman Y, Lasset C, Lazaro C, Lester J, Lesueur F, Liljegren A, Loud J, Lubiński J, Mai P, Manoukian S, Mari V, Mebirouk N, Meijers-Heijboer H, Meindl A, Mensenkamp A, Miller A, Montagna M, Mouret-Fourme E, Mukherjee S, Mulligan A, Nathanson K, Neuhausen S, Nevanlinna H, Niederacher D, Nielsen F, Nikitina-Zake L, Noguès C, Olah E, Olopade O, Ong K, O’Shaughnessy-Kirwan A, Osorio A, Ott C, Papi L, Park S, Parsons M, Pedersen I, Peissel B, Peixoto A, Peterlongo P, Pfeiler G, Phillips K, Prajzendanc K, Pujana M, Radice P, Ramser J, Ramus S, Rantala J, Rennert G, Risch H, Robson M, Rønlund K, Salani R, Schuster H, Senter L, Shah P, Sharma P, Side L, Singer C, Slavin T, Soucy P, Southey M, Spurdle A, Steinemann D, Steinsnyder Z, Stoppa-Lyonnet D, Sutter C, Tan Y, Teixeira M, Teo S, Thull D, Tischkowitz M, Tognazzo S, Toland A, Trainer A, Tung N, van Engelen K, van Rensburg E, Vega A, Vierstraete J, Wagner G, Walker L, Wang-Gohrke S, Wappenschmidt B, Weitzel J, Yadav S, Yang X, Yannoukakos D, Zimbalatti D, Offit K, Thomassen M, Couch F, Schmutzler R, Simard J, Easton D, Chenevix-Trench G, Antoniou A. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics In Medicine 2020, 22: 1653-1666. PMID: 32665703, PMCID: PMC7521995, DOI: 10.1038/s41436-020-0862-x.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerPathogenic variant carriersProspective cohortPolygenic risk scoresVariant carriersCancer riskRisk scoreStrong associationEOC riskHigh-grade serous epithelial ovarian cancerSerous epithelial ovarian cancerER-positive BCBRCA2 pathogenic variantsCarriers of BRCA1Absolute risk differenceEpithelial ovarian cancer riskGeneral population estimatesOvarian cancer riskHR estimatesBRCA2 pathogenic variant carriersBRCA1 carriersBRCA1/2 carriersOvarian cancerBC riskEstrogen receptorAssociation Between Breastfeeding and Ovarian Cancer Risk
Babic A, Sasamoto N, Rosner BA, Tworoger SS, Jordan SJ, Risch HA, Harris HR, Rossing MA, Doherty JA, Fortner RT, Chang-Claude J, Goodman MT, Thompson PJ, Moysich KB, Ness RB, Kjaer SK, Jensen A, Schildkraut JM, Titus LJ, Cramer DW, Bandera EV, Qin B, Sieh W, McGuire V, Sutphen R, Pearce CL, Wu AH, Pike M, Webb PM, Modugno F, Terry KL. Association Between Breastfeeding and Ovarian Cancer Risk. JAMA Oncology 2020, 6: e200421. PMID: 32239218, PMCID: PMC7118668, DOI: 10.1001/jamaoncol.2020.0421.Peer-Reviewed Original ResearchConceptsOvarian cancer riskInvasive ovarian cancerEpithelial ovarian cancerOvarian cancerCancer riskLower riskOdds ratioLogistic regressionHigh-grade serous subtypeHistotype-specific associationsMultivariable logistic regressionCase-control studyOvarian Cancer Association ConsortiumPolytomous logistic regressionParous womenEndometrioid cancerModifiable factorsPooled analysisSerous subtypeMAIN OUTCOMEBreastfeedingMore monthsOverall associationLethal typeCancer
2019
Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers
Qian F, Rookus MA, Leslie G, Risch HA, Greene MH, Aalfs CM, Adank MA, Adlard J, Agnarsson BA, Ahmed M, Aittomäki K, Andrulis IL, Arnold N, Arun BK, Ausems MGEM, Azzollini J, Barrowdale D, Barwell J, Benitez J, Białkowska K, Bonadona V, Borde J, Borg A, Bradbury AR, Brunet J, Buys SS, Caldés T, Caligo MA, Campbell I, Carter J, Chiquette J, Chung WK, Claes KBM, Collée JM, Collonge-Rame MA, Couch FJ, Daly MB, Delnatte C, Diez O, Domchek SM, Dorfling CM, Eason J, Easton DF, Eeles R, Engel C, Evans DG, Faivre L, Feliubadaló L, Foretova L, Friedman E, Frost D, Ganz PA, Garber J, Garcia-Barberan V, Gehrig A, Glendon G, Godwin AK, Gómez Garcia EB, Hamann U, Hauke J, Hopper JL, Hulick PJ, Imyanitov EN, Isaacs C, Izatt L, Jakubowska A, Janavicius R, John EM, Karlan BY, Kets CM, Laitman Y, Lázaro C, Leroux D, Lester J, Lesueur F, Loud JT, Lubiński J, Łukomska A, McGuffog L, Mebirouk N, Meijers-Heijboer HEJ, Meindl A, Miller A, Montagna M, Mooij TM, Mouret-Fourme E, Nathanson KL, Nehoray B, Neuhausen SL, Nevanlinna H, Nielsen FC, Offit K, Olah E, Ong KR, Oosterwijk JC, Ottini L, Parsons MT, Peterlongo P, Pfeiler G, Pradhan N, Radice P, Ramus SJ, Rantala J, Rennert G, Robson M, Rodriguez GC, Salani R, Scheuner MT, Schmutzler RK, Shah PD, Side LE, Simard J, Singer CF, Steinemann D, Stoppa-Lyonnet D, Tan YY, Teixeira MR, Terry MB, Thomassen M, Tischkowitz M, Tognazzo S, Toland AE, Tung N, van Asperen CJ, van Engelen K, van Rensburg EJ, Venat-Bouvet L, Vierstraete J, Wagner G, Walker L, Weitzel JN, Yannoukakos D, Antoniou A, Goldgar D, Olopade O, Chenevix-Trench G, Rebbeck T, Huo D. Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. British Journal Of Cancer 2019, 121: 180-192. PMID: 31213659, PMCID: PMC6738050, DOI: 10.1038/s41416-019-0492-8.Peer-Reviewed Original ResearchConceptsBody mass indexOvarian cancer riskBRCA1/2 mutation carriersBRCA2 mutation carriersCancer riskMutation carriersMass indexGeneral populationHigher ovarian cancer riskHigher body mass indexGenetic scoreOvarian cancer casesMendelian randomisation studyMendelian randomisation approachConsortium of InvestigatorsPostmenopausal womenPremenopausal womenMenopausal statusCancer casesCox modelConclusionOur observationsRandomisation approachM2 increaseRiskPositive associationAssociation between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study
Harris HR, Cushing-Haugen KL, Webb PM, Nagle CM, Jordan SJ, Group A, Risch H, Rossing M, Doherty J, Goodman M, Modugno F, Ness R, Moysich K, Kjær S, Høgdall E, Jensen A, Schildkraut J, Berchuck A, Cramer D, Bandera E, Rodriguez L, Wentzensen N, Kotsopoulos J, Narod S, McLaughlin J, Anton-Culver H, Ziogas A, Pearce C, Wu A, Lindström S, Terry K. Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study. International Journal Of Epidemiology 2019, 48: 822-830. PMID: 31211375, PMCID: PMC6659359, DOI: 10.1093/ije/dyz113.Peer-Reviewed Original ResearchConceptsPolycystic ovary syndromeOvarian cancer riskOvarian Cancer Association ConsortiumSelf-reported polycystic ovary syndromeInvasive ovarian cancerOvarian cancerCancer riskOvary syndromeInverse associationOral contraceptive useReproductive-aged womenBody mass indexSingle nucleotide polymorphismsStrong inverse associationComplex endocrine disorderObservational study resultsMendelian randomization studyEuropean ancestry womenEndometrioid tumorsMass indexDecreased riskEndocrine disordersSpecific histotypesContraceptive useAged women
2018
Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study
Dixon-Suen SC, Nagle CM, Thrift AP, Pharoah PDP, Ewing A, Pearce CL, Zheng W, Australian Ovarian Cancer Study Group, Chenevix-Trench G, Fasching PA, Beckmann MW, Lambrechts D, Vergote I, Lambrechts S, Van Nieuwenhuysen E, Rossing MA, Doherty JA, Wicklund KG, Chang-Claude J, Jung AY, Moysich KB, Odunsi K, Goodman MT, Wilkens LR, Thompson PJ, Shvetsov YB, Dörk T, Park-Simon TW, Hillemanns P, Bogdanova N, Butzow R, Nevanlinna H, Pelttari LM, Leminen A, Modugno F, Ness RB, Edwards RP, Kelley JL, Heitz F, du Bois A, Harter P, Schwaab I, Karlan BY, Lester J, Orsulic S, Rimel BJ, Kjær SK, Høgdall E, Jensen A, Goode EL, Fridley BL, Cunningham JM, Winham SJ, Giles GG, Bruinsma F, Milne RL, Southey MC, Hildebrandt MAT, Wu X, Lu KH, Liang D, Levine DA, Bisogna M, Schildkraut JM, Berchuck A, Cramer DW, Terry KL, Bandera EV, Olson SH, Salvesen HB, Thomsen LCV, Kopperud RK, Bjorge L, Kiemeney LA, Massuger LFAG, Pejovic T, Bruegl A, Cook LS, Le ND, Swenerton KD, Brooks-Wilson A, Kelemen LE, Lubiński J, Huzarski T, Gronwald J, Menkiszak J, Wentzensen N, Brinton L, Yang H, Lissowska J, Høgdall CK, Lundvall L, Song H, Tyrer JP, Campbell I, Eccles D, Paul J, Glasspool R, Siddiqui N, Whittemore AS, Sieh W, McGuire V, Rothstein JH, Narod SA, Phelan C, Risch HA, McLaughlin JR, Anton-Culver H, Ziogas A, Menon U, Gayther SA, Ramus SJ, Gentry-Maharaj A, Wu AH, Pike MC, Tseng CC, Kupryjanczyk J, Dansonka-Mieszkowska A, Budzilowska A, Rzepecka IK, Webb PM, on behalf of the Ovarian Cancer Association Consortium. Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. British Journal Of Cancer 2018, 118: 1123-1129. PMID: 29555990, PMCID: PMC5931085, DOI: 10.1038/s41416-018-0011-3.Peer-Reviewed Original ResearchConceptsOvarian cancer riskMendelian randomisationOdds ratioOvarian cancerCancer riskStudy-specific odds ratiosConfidence intervalsMendelian randomisation studyBackgroundObservational studiesOvarian carcinogenesisRisk scoreAdult heightConsortium studySingle nucleotide polymorphismsRiskCancerGenetic propensityPolycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium
Harris HR, Babic A, Webb PM, Nagle CM, Jordan SJ, Group O, Risch H, Rossing M, Doherty J, Goodman M, Modugno F, Ness R, Moysich K, Kjær S, Høgdall E, Jensen A, Schildkraut J, Berchuck A, Cramer D, Bandera E, Wentzensen N, Kotsopoulos J, Narod S, Phelan C, McLaughlin J, Anton-Culver H, Ziogas A, Pearce C, Wu A, Terry K, Consortium O. Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers & Prevention 2018, 27: 174-182. PMID: 29141849, PMCID: PMC5877463, DOI: 10.1158/1055-9965.epi-17-0655.Peer-Reviewed Original ResearchConceptsInvasive ovarian cancerPolycystic ovary syndromeOvarian cancer riskMenstrual cycle lengthOvarian cancerCancer riskDecreased riskSelf-reported polycystic ovary syndromeLogistic regressionCycle lengthStudy-specific ORsIrregular menstrual cyclesSerous borderline tumorsRisk factor associationsCase-control studyOvarian cancer histotypesPolytomous logistic regressionMucinous tumorsOvary syndromeBorderline tumorsHistologic subtypeOvarian diseaseMenstrual cycleCancer histotypesHistotype
2017
Menstrual pain and risk of epithelial ovarian cancer: Results from the Ovarian Cancer Association Consortium
Babic A, Harris HR, Vitonis AF, Titus LJ, Jordan SJ, Webb PM, Group A, Risch H, Rossing M, Doherty J, Wicklund K, Goodman M, Modugno F, Moysich K, Ness R, Kjaer S, Schildkraut J, Berchuck A, Pearce C, Wu A, Cramer D, Terry K. Menstrual pain and risk of epithelial ovarian cancer: Results from the Ovarian Cancer Association Consortium. International Journal Of Cancer 2017, 142: 460-469. PMID: 28833087, PMCID: PMC7580880, DOI: 10.1002/ijc.31010.Peer-Reviewed Original ResearchConceptsSevere menstrual painMenstrual painOvarian cancerOdds ratioHistologic subtypePotential confoundersIncreased ovarian cancer riskLogistic regressionSpecific histologic subtypesCommon gynecological conditionEpithelial ovarian cancerMultivariate logistic regressionOvarian cancer riskCase-control studyOvarian Cancer Association ConsortiumInternational pooled analysisUse of hormonesSevere painGynecological conditionsProspective studyPooled analysisClear cellsUndiagnosed endometriosisCancer riskMultinomial logistic regression
2016
Pelvic Inflammatory Disease and the Risk of Ovarian Cancer and Borderline Ovarian Tumors: A Pooled Analysis of 13 Case-Control Studies
Rasmussen CB, Kjaer SK, Albieri V, Bandera EV, Doherty JA, Høgdall E, Webb PM, Jordan SJ, Rossing MA, Wicklund KG, Goodman MT, Modugno F, Moysich KB, Ness RB, Edwards RP, Schildkraut JM, Berchuck A, Olson SH, Kiemeney LA, Massuger LF, Narod SA, Phelan CM, Anton-Culver H, Ziogas A, Wu AH, Pearce CL, Risch HA, Jensen A, Consortium O. Pelvic Inflammatory Disease and the Risk of Ovarian Cancer and Borderline Ovarian Tumors: A Pooled Analysis of 13 Case-Control Studies. American Journal Of Epidemiology 2016, 185: 8-20. PMID: 27941069, PMCID: PMC5209588, DOI: 10.1093/aje/kww161.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Ovarian EpithelialCase-Control StudiesComorbidityContraceptives, Oral, HormonalFamily HealthFemaleGenetic Predisposition to DiseaseHormone Replacement TherapyHumansHysterectomyNeoplasms, Glandular and EpithelialOvarian NeoplasmsPelvic Inflammatory DiseaseProtective FactorsReproductive HistoryRisk FactorsSterilization, TubalTalcConceptsPelvic inflammatory diseaseOvarian cancer riskBorderline ovarian tumorsCase-control studyOvarian Cancer Association ConsortiumBorderline tumorsOvarian cancerCancer riskOvarian tumorsInflammatory diseasesOdds ratioEpisodes of PIDHistory of PIDStudy-specific odds ratiosLow-grade serous tumorsHistotype-specific associationsEpithelial ovarian cancerPooled odds ratioRandom-effects modelSerous tumorsPooled analysisOvarian carcinogenesisTumor behaviorTumorsCancerFrequency of germline PALB2 mutations among women with epithelial ovarian cancer
Kotsopoulos J, Sopik V, Rosen B, Fan I, McLaughlin JR, Risch H, Sun P, Narod SA, Akbari MR. Frequency of germline PALB2 mutations among women with epithelial ovarian cancer. Familial Cancer 2016, 16: 29-34. PMID: 27631815, DOI: 10.1007/s10689-016-9919-z.Peer-Reviewed Original ResearchConceptsGermline PALB2 mutationsPALB2 mutationsOvarian cancerEpithelial ovarian cancer patientsYear of diagnosisEpithelial ovarian cancerOvarian cancer patientsOvarian cancer riskMean ageCancer patientsControl subjectsNational HeartMedical recordsClinical recommendationsSurvival statusCancer riskClinical informationUnselected populationClinical relevanceBRCA2 genesGermline mutationsCancerFurther studiesPatientsPrevalenceAssociation of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study
Ong JS, Cuellar-Partida G, Lu Y, Study A, Fasching P, Hein A, Burghaus S, Beckmann M, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Vanderstichele A, Doherty J, Rossing M, Chang-Claude J, Eilber U, Rudolph A, Wang-Gohrke S, Goodman M, Bogdanova N, Dörk T, Dürst M, Hillemanns P, Runnebaum I, Antonenkova N, Butzow R, Leminen A, Nevanlinna H, Pelttari L, Edwards R, Kelley J, Modugno F, Moysich K, Ness R, Cannioto R, Høgdall E, Høgdall C, Jensen A, Giles G, Bruinsma F, Kjaer S, Hildebrandt M, Liang D, Lu K, Wu X, Bisogna M, Dao F, Levine D, Cramer D, Terry K, Tworoger S, Stampfer M, Missmer S, Bjorge L, Salvesen H, Kopperud R, Bischof K, Aben K, Kiemeney L, Massuger L, Brooks-Wilson A, Olson S, McGuire V, Rothstein J, Sieh W, Whittemore A, Cook L, Le N, Gilks C, Gronwald J, Jakubowska A, Lubiński J, Kluz T, Song H, Tyrer J, Wentzensen N, Brinton L, Trabert B, Lissowska J, McLaughlin J, Narod S, Phelan C, Anton-Culver H, Ziogas A, Eccles D, Campbell I, Gayther S, Gentry-Maharaj A, Menon U, Ramus S, Wu A, Dansonka-Mieszkowska A, Kupryjanczyk J, Timorek A, Szafron L, Cunningham J, Fridley B, Winham S, Bandera E, Poole E, Morgan T, Risch H, Goode E, Schildkraut J, Pearce C, Berchuck A, Pharoah P, Chenevix-Trench G, Gharahkhani P, Neale R, Webb P, MacGregor S. Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. International Journal Of Epidemiology 2016, 45: 1619-1630. PMID: 27594614, PMCID: PMC5100621, DOI: 10.1093/ije/dyw207.Peer-Reviewed Original ResearchConceptsVitamin D levelsOvarian cancerVitamin DD levelsOdds ratioObservational studySingle nucleotide polymorphismsD concentrationsPlasma vitamin D levelsHigh-grade serous ovarian cancerHigh-grade serous epithelial ovarian cancerMendelian randomizationSerous epithelial ovarian cancerEpithelial ovarian cancer riskEpithelial ovarian cancerOvarian cancer riskOvarian Cancer Association ConsortiumSerous ovarian cancerObservational epidemiological studiesTwo-sample MR approachInverse variance weightingMendelian randomization studyOvarian cancer susceptibilityCancer preventionCancer riskChronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk
Cannioto R, LaMonte M, Risch H, Hong C, Sucheston-Campbell L, Eng K, Szender J, Chang-Claude J, Schmalfeldt B, Klapdor R, Gower E, Minlikeeva A, Zirpoli G, Bandera E, Berchuck A, Cramer D, Doherty J, Edwards R, Fridley B, Goode E, Goodman M, Hogdall E, Hosono S, Jensen A, Jordan S, Kjaer S, Matsuo K, Ness R, Olsen C, Olson S, Pearce C, Pike M, Rossing M, Szamreta E, Thompson P, Tseng C, Vierkant R, Webb P, Wentzensen N, Wicklund K, Winham S, Wu A, Modugno F, Schildkraut J, Terry K, Kelemen L, Moysich K. Chronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk. Obstetrical & Gynecological Survey 2016, 71: 528-530. DOI: 10.1097/ogx.0000000000000357.Peer-Reviewed Original ResearchChronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk: Evidence from the Ovarian Cancer Association Consortium
Cannioto R, LaMonte MJ, Risch HA, Hong CC, Sucheston-Campbell LE, Eng KH, Szender JB, Chang-Claude J, Schmalfeldt B, Klapdor R, Gower E, Minlikeeva AN, Zirpoli GR, Bandera EV, Berchuck A, Cramer D, Doherty JA, Edwards RP, Fridley BL, Goode EL, Goodman MT, Hogdall E, Hosono S, Jensen A, Jordan S, Group O, Kjaer S, Matsuo K, Ness R, Olsen C, Olson S, Pearce C, Pike M, Rossing M, Szamreta E, Thompson P, Tseng C, Vierkant R, Webb P, Wentzensen N, Wicklund K, Winham S, Wu A, Modugno F, Schildkraut J, Terry K, Kelemen L, Moysich K. Chronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers & Prevention 2016, 25: 1114-1124. PMID: 27197285, PMCID: PMC4930728, DOI: 10.1158/1055-9965.epi-15-1330.Peer-Reviewed Original ResearchConceptsRecreational physical inactivityRecreational physical activityPhysical inactivityEOC riskPooled analysisPhysical activityWeekly recreational physical activityLarge pooled analysisIndependent risk factorEpithelial ovarian cancer riskPhysical activity guidelinesBody mass indexMultivariable logistic regressionConfidence intervalsOvarian cancer riskOvarian Cancer Association ConsortiumDose of activityMenopausal statusChronic inactivityActivity guidelinesEOC patientsMass indexSignificant positive associationBody of evidenceIndependent associationAdult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study
Dixon SC, Nagle CM, Thrift AP, Pharoah PD, Pearce CL, Zheng W, Painter JN, Study A, Chenevix-Trench G, Fasching P, Beckmann M, Lambrechts D, Vergote I, Lambrechts S, Van Nieuwenhuysen E, Rossing M, Doherty J, Wicklund K, Chang-Claude J, Rudolph A, Moysich K, Odunsi K, Goodman M, Wilkens L, Thompson P, Shvetsov Y, Dörk T, Park-Simon T, Hillemanns P, Bogdanova N, Butzow R, Nevanlinna H, Pelttari L, Leminen A, Modugno F, Ness R, Edwards R, Kelley J, Heitz F, Karlan B, Kjær S, Høgdall E, Jensen A, Goode E, Fridley B, Cunningham J, Winham S, Giles G, Bruinsma F, Milne R, Southey M, Hildebrandt M, Wu X, Lu K, Liang D, Levine D, Bisogna M, Schildkraut J, Berchuck A, Cramer D, Terry K, Bandera E, Olson S, Salvesen H, Thomsen L, Kopperud R, Bjorge L, Kiemeney L, Massuger L, Pejovic T, Cook L, Le N, Swenerton K, Brooks-Wilson A, Kelemen L, Lubiński J, Huzarski T, Gronwald J, Menkiszak J, Wentzensen N, Brinton L, Yang H, Lissowska J, Høgdall C, Lundvall L, Song H, Tyrer J, Campbell I, Eccles D, Paul J, Glasspool R, Siddiqui N, Whittemore A, Sieh W, McGuire V, Rothstein J, Narod S, Phelan C, Risch H, McLaughlin J, Anton-Culver H, Ziogas A, Menon U, Gayther S, Ramus S, Gentry-Maharaj A, Wu A, Pike M, Tseng C, Kupryjanczyk J, Dansonka-Mieszkowska A, Budzilowska A, Spiewankiewicz B, Webb P, Consortium O. Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. International Journal Of Epidemiology 2016, 45: 884-895. PMID: 27401727, PMCID: PMC5644573, DOI: 10.1093/ije/dyw158.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAllelesBody Mass IndexFemaleGenetic MarkersGenome-Wide Association StudyGenotypeHumansLogistic ModelsMendelian Randomization AnalysisMeta-Analysis as TopicMiddle AgedMultivariate AnalysisObesityOvarian NeoplasmsPolymorphism, Single NucleotideRisk FactorsYoung AdultConceptsBody mass indexOvarian cancerSerous cancerMass indexOdds ratioObservational studyMendelian randomizationStudy-specific odds ratiosHigher body mass indexAdult body mass indexGrade serous ovarian cancerConfidence intervalsOvarian cancer riskOvarian Cancer Association ConsortiumSerous ovarian cancerWeighted genetic risk scoreLack of associationMendelian randomization studyGenetic risk scoreStrength of associationHistological subtypesRisk factorsCancer riskRisk scoreHGSC subtype
2015
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers
Meeks HD, Song H, Michailidou K, Bolla MK, Dennis J, Wang Q, Barrowdale D, Frost D, EMBRACE, McGuffog L, Ellis S, Feng B, Buys S, Hopper J, Southey M, Tesoriero A, Investigators K, James P, Bruinsma F, Campbell I, Group A, Broeks A, Schmidt M, Hogervorst F, HEBON, Beckman M, Fasching P, Fletcher O, Johnson N, Sawyer E, Riboli E, Banerjee S, Menon U, Tomlinson I, Burwinkel B, Hamann U, Marme F, Rudolph A, Janavicius R, Tihomirova L, Tung N, Garber J, Cramer D, Terry K, Poole E, Tworoger S, Dorfling C, van Rensburg E, Godwin A, Guénel P, Truong T, Collaborators G, Stoppa-Lyonnet D, Damiola F, Mazoyer S, Sinilnikova O, Isaacs C, Maugard C, Bojesen S, Flyger H, Gerdes A, Hansen T, Jensen A, Kjaer S, Hogdall C, Hogdall E, Pedersen I, Thomassen M, Benitez J, González-Neira A, Osorio A, de la Hoya M, Segura P, Diez O, Lazaro C, Brunet J, Anton-Culver H, Eunjung L, John E, Neuhausen S, Ding Y, Castillo D, Weitzel J, Ganz P, Nussbaum R, Chan S, Karlan B, Lester J, Wu A, Gayther S, Ramus S, Sieh W, Whittermore A, Monteiro A, Phelan C, Terry M, Piedmonte M, Offit K, Robson M, Levine D, Moysich K, Cannioto R, Olson S, Daly M, Nathanson K, Domchek S, Lu K, Liang D, Hildebrant M, Ness R, Modugno F, Pearce L, Goodman M, Thompson P, Brenner H, Butterbach K, Meindl A, Hahnen E, Wappenschmidt B, Brauch H, Brüning T, Blomqvist C, Khan S, Nevanlinna H, Pelttari L, Aittomäki K, Butzow R, Bogdanova N, Dörk T, Lindblom A, Margolin S, Rantala J, Kosma V, Mannermaa A, Lambrechts D, Neven P, Claes K, Van Maerken T, Chang-Claude J, Flesch-Janys D, Heitz F, Varon-Mateeva R, Peterlongo P, Radice P, Viel A, Barile M, Peissel B, Manoukian S, Montagna M, Oliani C, Peixoto A, Teixeira M, Collavoli A, Hallberg E, Olson J, Goode E, Hart S, Shimelis H, Cunningham J, Giles G, Milne R, Healey S, Tucker K, Haiman C, Henderson B, Goldberg M, Tischkowitz M, Simard J, Soucy P, Eccles D, Le N, Borresen-Dale A, Kristensen V, Salvesen H, Bjorge L, Bandera E, Risch H, Zheng W, Beeghly-Fadiel A, Cai H, Pylkäs K, Tollenaar R, van der Ouweland A, Andrulis I, Knight J, OCGN, Narod S, Devilee P, Winqvist R, Figueroa J, Greene M, L. P, Loud J, García-Closas M, Schoemaker M, Czene K, Darabi H, McNeish I, Siddiquil N, Glasspool R, Kwong A, Park S, Teo S, Yoon S, Matsuo K, Hosono S, Woo Y, Gao Y, Foretova L, Singer C, Rappaport-Feurhauser C, Friedman E, Laitman Y, Rennert G, Imyanitov E, Hulick P, Olopade O, Senter L, Olah E, Doherty J, Schildkraut J, Koppert L, Kiemeney L, Massuger L, Cook L, Pejovic T, Li J, Borg A, Öfverholm A, Rossing M, Wentzensen N, Henriksson K, Cox A, Cross S, Pasini B, Shah M, Kabisch M, Torres D, Jakubowska A, Lubinski J, Gronwald J, Agnarsson B, Kupryjanczyk J, Moes-Sosnowska J, Fostira F, Konstantopoulou I, Slager S, Jones M, in the genome P, Antoniou A, Berchuck A, Swerdlow A, Chenevix-Trench G, Dunning A, Pharoah P, Hall P, Easton D, Couch F, Spurdle A, Goldgar D. BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. Journal Of The National Cancer Institute 2015, 108: djv315. PMID: 26586665, PMCID: PMC4907358, DOI: 10.1093/jnci/djv315.Peer-Reviewed Original ResearchConceptsOvarian cancerBreast cancerVariant carriersCancer riskEstrogen receptor-negative breast cancerReceptor-negative breast cancerCancer case patientsInvasive ovarian cancerHormone-related cancersProstate cancer riskConfidence intervalsOvarian cancer riskSignificant inverse associationCox proportional hazardsSerous ovarian cancerRisk of breastBRCA1 mutation carriersPathogenic BRCA2 variantsControl patientsCase patientsInverse associationOdds ratioProstate cancerMutation carriersProportional hazardsEvidence of a genetic link between endometriosis and ovarian cancer
Lee A, Templeman C, Stram D, Beesley J, Tyrer J, Berchuck A, Pharoah P, Chenevix-Trench G, Pearce C, Consortium O, Ness R, Dansonka-Mieszkowska A, Gentry-Maharaj A, Hein A, Whittemore A, Jensen A, du Bois A, Brooks-Wilson A, Rudolph A, Jakubowska A, Wu A, Ziogas A, Ekici A, Leminen A, Study A, Group A, Rosen B, Spiewankiewicz B, Karlan B, Trabert B, Fridley B, Gilks C, Krakstad C, Phelan C, Cybulski C, Walsh C, Hogdall C, Cramer D, Huntsman D, Eccles D, Lambrechts D, Liang D, Levine D, Iversen E, Bandera E, Poole E, Goode E, Van Nieuwenhuysen E, Hogdall E, Bruinsma F, Heitz F, Modugno F, Giles G, Risch H, Baker H, Salvesen H, Nevanlinna H, Anton-Culver H, Song H, McNeish I, Campbell I, Vergote I, Runnebaum I, Tangen I, Schwaab I, Gronwald J, Paul J, Lubinski J, Doherty J, Chang-Claude J, Lester J, Schildkraut J, McLaughlin J, Lissowska J, Kupryjanczyk J, Tyrer J, Kelley J, Rothstein J, Cunningham J, Lu K, Carty K, Terry K, Aben K, Moysich K, Wicklund K, Odunsi K, Kiemeney L, Sucheston-Campbell L, Lundvall L, Massuger L, Pelttari L, Kelemen L, Cook L, Bjorge L, Nedergaard L, Brinton L, Wilkens L, Pike M, Goodman M, Bisogna M, Rossing M, Beckmann M, Dürst M, Southey M, Kellar M, Hildebrandt M, Siddiqui N, Antonenkova N, Bogdanova N, Le N, Wentzensen N, Thompson P, Harrington P, Webb P, Fasching P, Hillemanns P, Harter P, Sobiczewski P, Weber R, Butzow R, Edwards R, Vierkant R, Glasspool R, Orsulic S, Lambrechts S, Olson S, Wang-Gohrke S, Lele S, Tworoger S, Gayther S, Missmer S, Narod S, Ramus S, Kjaer S, Pejovic T, Dörk T, Eilber U, Menon U, McGuire V, Sieh W, Wu X, Bean Y, Shvetsov Y. Evidence of a genetic link between endometriosis and ovarian cancer. Fertility And Sterility 2015, 105: 35-43.e10. PMID: 26477498, PMCID: PMC5068352, DOI: 10.1016/j.fertnstert.2015.09.023.Peer-Reviewed Original ResearchEpithelial‐Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk
Amankwah EK, Lin H, Tyrer JP, Lawrenson K, Dennis J, Chornokur G, Aben KK, Anton‐Culver H, Antonenkova N, Bruinsma F, Bandera EV, Bean YT, Beckmann MW, Bisogna M, Bjorge L, Bogdanova N, Brinton LA, Brooks‐Wilson A, Bunker CH, Butzow R, Campbell IG, Carty K, Chen Z, Chen YA, Chang‐Claude J, Cook LS, Cramer DW, Cunningham JM, Cybulski C, Dansonka‐Mieszkowska A, du Bois A, Despierre E, Dicks E, Doherty JA, Dörk T, Dürst M, Easton DF, Eccles DM, Edwards RP, Ekici AB, Fasching PA, Fridley BL, Gao Y, Gentry‐Maharaj A, Giles GG, Glasspool R, Goodman MT, Gronwald J, Harrington P, Harter P, Hasmad HN, Hein A, Heitz F, Hildebrandt MA, Hillemanns P, Hogdall CK, Hogdall E, Hosono S, Iversen ES, Jakubowska A, Jensen A, Ji B, Karlan BY, Jim H, Kellar M, Kiemeney LA, Krakstad C, Kjaer SK, Kupryjanczyk J, Lambrechts D, Lambrechts S, Le ND, Lee AW, Lele S, Leminen A, Lester J, Levine DA, Liang D, Lim BK, Lissowska J, Lu K, Lubinski J, Lundvall L, Massuger LF, Matsuo K, McGuire V, McLaughlin JR, McNeish I, Menon U, Milne RL, Modugno F, Moysich KB, Ness RB, Nevanlinna H, Eilber U, Odunsi K, Olson SH, Orlow I, Orsulic S, Weber RP, Paul J, Pearce CL, Pejovic T, Pelttari LM, Permuth‐Wey J, Pike MC, Poole EM, Risch HA, Rosen B, Rossing MA, Rothstein JH, Rudolph A, Runnebaum IB, Rzepecka IK, Salvesen HB, Schernhammer E, Schwaab I, Shu X, Shvetsov YB, Siddiqui N, Sieh W, Song H, Southey MC, Spiewankiewicz B, Sucheston‐Campbell L, Teo S, Terry KL, Thompson PJ, Thomsen L, Tangen IL, Tworoger SS, van Altena A, Vierkant RA, Vergote I, Walsh CS, Wang‐Gohrke S, Wentzensen N, Whittemore AS, Wicklund KG, Wilkens LR, Wu AH, Wu X, Woo Y, Yang H, Zheng W, Ziogas A, Kelemen LE, Berchuck A, group G, Schildkraut J, Ramus S, Goode E, Monteiro A, Gayther S, Narod S, Pharoah P, Sellers T, Phelan C. Epithelial‐Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genetic Epidemiology 2015, 39: 689-697. PMID: 26399219, PMCID: PMC4721602, DOI: 10.1002/gepi.21921.Peer-Reviewed Original Research
2014
Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study
Lee AW, Tyrer JP, Doherty JA, Stram DA, Kupryjanczyk J, Dansonka-Mieszkowska A, Plisiecka-Halasa J, Spiewankiewicz B, Myers EJ, Study A, Group A, Chenevix-Trench G, Fasching PA, Beckmann MW, Ekici AB, Hein A, Vergote I, Van Nieuwenhuysen E, Lambrechts D, Wicklund KG, Eilber U, Wang-Gohrke S, Chang-Claude J, Rudolph A, Sucheston-Campbell L, Odunsi K, Moysich KB, Shvetsov YB, Thompson PJ, Goodman MT, Wilkens LR, Dörk T, Hillemanns P, Dürst M, Runnebaum IB, Bogdanova N, Pelttari LM, Nevanlinna H, Leminen A, Edwards RP, Kelley JL, Harter P, Schwaab I, Heitz F, du Bois A, Orsulic S, Lester J, Walsh C, Karlan BY, Hogdall E, Kjaer SK, Jensen A, Vierkant RA, Cunningham JM, Goode EL, Fridley BL, Southey MC, Giles GG, Bruinsma F, Wu X, Hildebrandt MA, Lu K, Liang D, Bisogna M, Levine DA, Weber RP, Schildkraut JM, Iversen ES, Berchuck A, Terry KL, Cramer DW, Tworoger SS, Poole EM, Olson SH, Orlow I, Bandera EV, Bjorge L, Tangen IL, Salvesen HB, Krakstad C, Massuger LF, Kiemeney LA, Aben KK, van Altena AM, Bean Y, Pejovic T, Kellar M, Le ND, Cook LS, Kelemen LE, Brooks-Wilson A, Lubinski J, Gronwald J, Cybulski C, Jakubowska A, Wentzensen N, Brinton LA, Lissowska J, Yang H, Nedergaard L, Lundvall L, Hogdall C, Song H, Campbell IG, Eccles D, Glasspool R, Siddiqui N, Carty K, Paul J, McNeish IA, Sieh W, McGuire V, Rothstein JH, Whittemore AS, McLaughlin JR, Risch HA, Phelan CM, Anton-Culver H, Ziogas A, Menon U, Ramus SJ, Gentry-Maharaj A, Harrington P, Pike MC, Modugno F, Rossing MA, Ness RB, Pharoah PD, Stram DO, Wu AH, Pearce CL. Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Gynecologic Oncology 2014, 136: 542-548. PMID: 25528498, PMCID: PMC4892108, DOI: 10.1016/j.ygyno.2014.12.017.Peer-Reviewed Original ResearchConceptsOvarian cancer riskOvarian Cancer StudyCancer riskGene-level associationsOnly modest associationsUnconditional logistic regressionCancer studiesHormone-related diseasesPathway genesGonadotropin hypothesisEtiologic roleGenome-wide significant associationOvarian cancerProstate cancerLarger sample sizeGonadotropinSignificant associationDisease riskModest associationLogistic regressionGene-level testsHigh-penetrance susceptibility genesCandidate gene studiesStrong genetic basisUnderstanding of biologyAspirin, Nonaspirin Nonsteroidal Anti-inflammatory Drug, and Acetaminophen Use and Risk of Invasive Epithelial Ovarian Cancer: A Pooled Analysis in the Ovarian Cancer Association Consortium
Trabert B, Ness RB, Lo-Ciganic WH, Murphy MA, Goode EL, Poole EM, Brinton LA, Webb PM, Nagle CM, Jordan SJ, Group T, Risch H, Rossing M, Doherty J, Goodman M, Lurie G, Kjær S, Hogdall E, Jensen A, Cramer D, Terry K, Vitonis A, Bandera E, Olson S, King M, Chandran U, Anton-Culver H, Ziogas A, Menon U, Gayther S, Ramus S, Gentry-Maharaj A, Wu A, Pearce C, Pike M, Berchuck A, Schildkraut J, Wentzensen N, Consortium O. Aspirin, Nonaspirin Nonsteroidal Anti-inflammatory Drug, and Acetaminophen Use and Risk of Invasive Epithelial Ovarian Cancer: A Pooled Analysis in the Ovarian Cancer Association Consortium. Journal Of The National Cancer Institute 2014, 106: djt431. PMID: 24503200, PMCID: PMC3924755, DOI: 10.1093/jnci/djt431.Peer-Reviewed Original ResearchMeSH KeywordsAcetaminophenAnticarcinogenic AgentsAnti-Inflammatory Agents, Non-SteroidalAspirinAustraliaCarcinoma, Ovarian EpithelialCase-Control StudiesData CollectionDenmarkDrug Administration ScheduleFemaleHumansIncidenceLogistic ModelsNeoplasms, Glandular and EpithelialOdds RatioOvarian NeoplasmsProtective AgentsRiskUnited KingdomUnited StatesConceptsNonaspirin nonsteroidal anti-inflammatory drugsNonaspirin NSAIDsInvasive epithelial ovarian cancerNonsteroidal anti-inflammatory drugsLow-dose aspirinEpithelial ovarian cancerOvarian cancerAnti-inflammatory drugsAspirin useAcetaminophen useOdds ratioPopulation-based case-control studyDaily aspirin usersRegular aspirin useOvarian cancer riskCase-control studyOvarian Cancer Association ConsortiumHigh-dose usageDose of useAspirin regimenAnalgesic useAspirin usersCardiovascular eventsDose aspirinCase patientsRisk of Ovarian Cancer and the NF-κB Pathway: Genetic Association with IL1A and TNFSF10
Charbonneau B, Block MS, Bamlet WR, Vierkant RA, Kalli KR, Fogarty Z, Rider DN, Sellers TA, Tworoger SS, Poole E, Risch HA, Salvesen HB, Kiemeney LA, Baglietto L, Giles GG, Severi G, Trabert B, Wentzensen N, Chenevix-Trench G, group F, Whittemore AS, Sieh W, Chang-Claude J, Bandera EV, Orlow I, Terry K, Goodman MT, Thompson PJ, Cook LS, Rossing MA, Ness RB, Narod SA, Kupryjanczyk J, Lu K, Butzow R, Dörk T, Pejovic T, Campbell I, Le ND, Bunker CH, Bogdanova N, Runnebaum IB, Eccles D, Paul J, Wu AH, Gayther SA, Hogdall E, Heitz F, Kaye SB, Karlan BY, Anton-Culver H, Gronwald J, Hogdall CK, Lambrechts D, Fasching PA, Menon U, Schildkraut J, Pearce CL, Levine DA, Kjaer SK, Cramer D, Flanagan JM, Phelan CM, Brown R, Massuger LF, Song H, Doherty JA, Krakstad C, Liang D, Odunsi K, Berchuck A, Jensen A, Lubiński J, Nevanlinna H, Bean YT, Lurie G, Ziogas A, Walsh C, Despierre E, Brinton L, Hein A, Rudolph A, Dansonka-Mieszkowska A, Olson SH, Harter P, Tyrer J, Vitonis AF, Brooks-Wilson A, Aben KK, Pike MC, Ramus SJ, Wik E, Cybulski C, Lin J, Sucheston L, Edwards R, McGuire V, Lester J, du Bois A, Lundvall L, Wang-Gohrke S, Szafron LM, Lambrechts S, Yang H, Beckmann MW, Pelttari LM, Van Altena AM, van den Berg D, Halle MK, Gentry-Maharaj A, Schwaab I, Chandran U, Menkiszak J, Ekici AB, Wilkens LR, Leminen A, Modugno F, Friel G, Rothstein JH, Vergote I, Garcia-Closas M, Hildebrandt MA, Sobiczewski P, Kelemen LE, Pharoah PD, Moysich K, Knutson KL, Cunningham JM, Fridley BL, Goode EL. Risk of Ovarian Cancer and the NF-κB Pathway: Genetic Association with IL1A and TNFSF10. Cancer Research 2014, 74: 852-861. PMID: 24272484, PMCID: PMC3946482, DOI: 10.1158/0008-5472.can-13-1051.Peer-Reviewed Original ResearchConceptsOvarian cancerNF-κB pathwaySingle nucleotide polymorphismsRisk factorsClear cell ovarian cancerEpidemiologic risk factorsOvarian cancer riskOvarian Cancer Association ConsortiumOvarian cancer associationRisk of endometriosisAlters riskBorderline tumorsClear cellsInterleukin-1αMissense single nucleotide polymorphismCancer riskProinflammatory genesCancer associationNF-κBCancerImportant mediatorDistinct genetic etiologiesControl casesExact mechanismGenotype analysis